Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:11 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT02196168 · National Cancer Institute (NCI) · PHASE2 · terminated · last registry update 2017-05-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Inadequate accrual rate” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against WEE1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2017-12-14Results posted on the registry: Merck Sharp & Dohme LLC, adavosertib + Topotecan (NCT01076400)
- 2017-09-07Results posted on the registry: Merck Sharp & Dohme LLC, adavosertib + Placebo (NCT01357161)
- 2017-05-03Also stopped (withdrawn): National Cancer Institute (NCI), Cytarabine + Filgrastim (NCT02791919)
- 2017-03-29Results posted on the registry: AstraZeneca, AZD1775 + AZD1775 Matching Placebo (NCT02087241)
- 2017-03-29Also stopped (terminated): AstraZeneca, AZD1775 + AZD1775 Matching Placebo (NCT02087241)
- 2016-06-14Results posted on the registry: AstraZeneca, AZD1775 + AZD1775 Placebo (NCT02087176)
- 2016-06-14Also stopped (terminated): AstraZeneca, AZD1775 + AZD1775 Placebo (NCT02087176)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision